Loading…
Structural basis for α-conotoxin potency and selectivity
This manuscript provides the solution structure of α-conotoxin MII[E11A] and compares surface electrostatic maps for α-conotoxins that selectively inhibit α3β2 versus α6β2 nAChRs. Parkinson’s disease is a debilitating movement disorder characterized by altered levels of α 6β 2∗ (∗ indicates the poss...
Saved in:
Published in: | Bioorganic & medicinal chemistry 2009-08, Vol.17 (16), p.5894-5899 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c448t-c9f2dbabdcef1e010487010ef858ca6bcc2e5d1b858ea1b8a49e572fb74538de3 |
---|---|
cites | cdi_FETCH-LOGICAL-c448t-c9f2dbabdcef1e010487010ef858ca6bcc2e5d1b858ea1b8a49e572fb74538de3 |
container_end_page | 5899 |
container_issue | 16 |
container_start_page | 5894 |
container_title | Bioorganic & medicinal chemistry |
container_volume | 17 |
creator | Turner, Matt Eidemiller, Seth Martin, Bryan Narver, Andrew Marshall, Joshua Zemp, Logan Cornell, Kenneth A. McIntosh, J.M. McDougal, Owen M. |
description | This manuscript provides the solution structure of α-conotoxin MII[E11A] and compares surface electrostatic maps for α-conotoxins that selectively inhibit α3β2 versus α6β2 nAChRs.
Parkinson’s disease is a debilitating movement disorder characterized by altered levels of α
6β
2∗ (∗ indicates the possible presence of additional subunits) nicotinic acetylcholine receptors (nAChRs) localized on presynaptic striatal catecholaminergic neurons. α-Conotoxin MII (α-CTx MII) is a highly useful ligand to probe α
6β
2 nAChRs structure and function, but it does not discriminate among closely related α
6∗ nAChR subtypes. Modification of the α-CTx MII primary sequence led to the identification of α-CTx MII[E11A], an analog with 500–5300-fold discrimination between α
6∗ subtypes found in both human and non-human primates. α-CTx MII[E11A] binds most strongly (femtomolar dissociation constant) to the high affinity α
6 nAChR, a subtype that is selectively lost in Parkinson’s disease. Here, we present the three-dimensional solution structure for α-CTx MII[E11A] as determined by two-dimensional
1H NMR spectroscopy to 0.13
±
0.09
Ǻ backbone and 0.45
±
0.08
Ǻ heavy atom root-mean-square deviation from mean structure. Structural comparisons suggest that the increased hydrophobic area of α-CTx MII[E11A] relative to other members of the α-CTx family may be responsible for its exceptionally high affinity for α6α4β2∗ nAChR as well as discrimination between α
6β
2 and α
3β
2 containing nAChRs. This finding may enable the rational design of novel peptide analogs that demonstrate enhanced specificity for α
6∗ nAChR subunit interfaces and provide a means to better understand nAChR structural determinants that modulate brain dopamine levels and the pathophysiology of Parkinson’s disease. |
doi_str_mv | 10.1016/j.bmc.2009.07.005 |
format | article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2754775</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0968089609006506</els_id><sourcerecordid>19628399</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-c9f2dbabdcef1e010487010ef858ca6bcc2e5d1b858ea1b8a49e572fb74538de3</originalsourceid><addsrcrecordid>eNp9kM1OAyEYRYnR2PrzAG7MbFzOCAwzQExMTONf0sSFuibAgNK0QwO0sY_li_hM0rSpunHDF8K9hy8HgDMEKwRRezmp1ExXGEJeQVpB2OyBISItKeuao30whLxlJWS8HYCjGCcQQkw4OgQDxFvMas6HgD-nsNBpEeS0UDK6WFgfiq_PUvveJ__h-mLuk-n1qpB9V0QzNTq5pUurE3Bg5TSa0-08Bq93ty-jh3L8dP84uhmXmhCWSs0t7pRUnTYWGYggYTSfxrKGadkqrbFpOqTy1cg8JOGmodgqSpqadaY-Btcb7nyhZiZj-pSXFfPgZjKshJdO_H3p3bt480uBaUMobTIAbQA6-BiDsbsugmLtUUxE9ijWHgWkInvMnfPfn_40tuJy4GIbkFHLqQ2y1y7uchjlFOZr0NUmZ7KipTNBRO2yTtO5kE2Kzrt_1vgGBjOTog</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Structural basis for α-conotoxin potency and selectivity</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Turner, Matt ; Eidemiller, Seth ; Martin, Bryan ; Narver, Andrew ; Marshall, Joshua ; Zemp, Logan ; Cornell, Kenneth A. ; McIntosh, J.M. ; McDougal, Owen M.</creator><creatorcontrib>Turner, Matt ; Eidemiller, Seth ; Martin, Bryan ; Narver, Andrew ; Marshall, Joshua ; Zemp, Logan ; Cornell, Kenneth A. ; McIntosh, J.M. ; McDougal, Owen M.</creatorcontrib><description>This manuscript provides the solution structure of α-conotoxin MII[E11A] and compares surface electrostatic maps for α-conotoxins that selectively inhibit α3β2 versus α6β2 nAChRs.
Parkinson’s disease is a debilitating movement disorder characterized by altered levels of α
6β
2∗ (∗ indicates the possible presence of additional subunits) nicotinic acetylcholine receptors (nAChRs) localized on presynaptic striatal catecholaminergic neurons. α-Conotoxin MII (α-CTx MII) is a highly useful ligand to probe α
6β
2 nAChRs structure and function, but it does not discriminate among closely related α
6∗ nAChR subtypes. Modification of the α-CTx MII primary sequence led to the identification of α-CTx MII[E11A], an analog with 500–5300-fold discrimination between α
6∗ subtypes found in both human and non-human primates. α-CTx MII[E11A] binds most strongly (femtomolar dissociation constant) to the high affinity α
6 nAChR, a subtype that is selectively lost in Parkinson’s disease. Here, we present the three-dimensional solution structure for α-CTx MII[E11A] as determined by two-dimensional
1H NMR spectroscopy to 0.13
±
0.09
Ǻ backbone and 0.45
±
0.08
Ǻ heavy atom root-mean-square deviation from mean structure. Structural comparisons suggest that the increased hydrophobic area of α-CTx MII[E11A] relative to other members of the α-CTx family may be responsible for its exceptionally high affinity for α6α4β2∗ nAChR as well as discrimination between α
6β
2 and α
3β
2 containing nAChRs. This finding may enable the rational design of novel peptide analogs that demonstrate enhanced specificity for α
6∗ nAChR subunit interfaces and provide a means to better understand nAChR structural determinants that modulate brain dopamine levels and the pathophysiology of Parkinson’s disease.</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/j.bmc.2009.07.005</identifier><identifier>PMID: 19628399</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ltd</publisher><subject>Amino Acid Sequence ; Anticonvulsants. Antiepileptics. Antiparkinson agents ; Biological and medical sciences ; Conotoxin ; Conotoxins - chemistry ; Conotoxins - pharmacology ; Humans ; Medical sciences ; Molecular Conformation ; Molecular Sequence Data ; Neuropharmacology ; Nicotinic acetylcholine receptor ; Nicotinic Antagonists - chemistry ; Nicotinic Antagonists - pharmacology ; NMR solution structure ; Parkinson Disease - physiopathology ; Parkinson’s disease ; Pharmacology. Drug treatments ; Protein Binding ; Protein Isoforms ; Receptors, Nicotinic - chemistry ; Receptors, Nicotinic - metabolism</subject><ispartof>Bioorganic & medicinal chemistry, 2009-08, Vol.17 (16), p.5894-5899</ispartof><rights>2009</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-c9f2dbabdcef1e010487010ef858ca6bcc2e5d1b858ea1b8a49e572fb74538de3</citedby><cites>FETCH-LOGICAL-c448t-c9f2dbabdcef1e010487010ef858ca6bcc2e5d1b858ea1b8a49e572fb74538de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21839295$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19628399$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Turner, Matt</creatorcontrib><creatorcontrib>Eidemiller, Seth</creatorcontrib><creatorcontrib>Martin, Bryan</creatorcontrib><creatorcontrib>Narver, Andrew</creatorcontrib><creatorcontrib>Marshall, Joshua</creatorcontrib><creatorcontrib>Zemp, Logan</creatorcontrib><creatorcontrib>Cornell, Kenneth A.</creatorcontrib><creatorcontrib>McIntosh, J.M.</creatorcontrib><creatorcontrib>McDougal, Owen M.</creatorcontrib><title>Structural basis for α-conotoxin potency and selectivity</title><title>Bioorganic & medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>This manuscript provides the solution structure of α-conotoxin MII[E11A] and compares surface electrostatic maps for α-conotoxins that selectively inhibit α3β2 versus α6β2 nAChRs.
Parkinson’s disease is a debilitating movement disorder characterized by altered levels of α
6β
2∗ (∗ indicates the possible presence of additional subunits) nicotinic acetylcholine receptors (nAChRs) localized on presynaptic striatal catecholaminergic neurons. α-Conotoxin MII (α-CTx MII) is a highly useful ligand to probe α
6β
2 nAChRs structure and function, but it does not discriminate among closely related α
6∗ nAChR subtypes. Modification of the α-CTx MII primary sequence led to the identification of α-CTx MII[E11A], an analog with 500–5300-fold discrimination between α
6∗ subtypes found in both human and non-human primates. α-CTx MII[E11A] binds most strongly (femtomolar dissociation constant) to the high affinity α
6 nAChR, a subtype that is selectively lost in Parkinson’s disease. Here, we present the three-dimensional solution structure for α-CTx MII[E11A] as determined by two-dimensional
1H NMR spectroscopy to 0.13
±
0.09
Ǻ backbone and 0.45
±
0.08
Ǻ heavy atom root-mean-square deviation from mean structure. Structural comparisons suggest that the increased hydrophobic area of α-CTx MII[E11A] relative to other members of the α-CTx family may be responsible for its exceptionally high affinity for α6α4β2∗ nAChR as well as discrimination between α
6β
2 and α
3β
2 containing nAChRs. This finding may enable the rational design of novel peptide analogs that demonstrate enhanced specificity for α
6∗ nAChR subunit interfaces and provide a means to better understand nAChR structural determinants that modulate brain dopamine levels and the pathophysiology of Parkinson’s disease.</description><subject>Amino Acid Sequence</subject><subject>Anticonvulsants. Antiepileptics. Antiparkinson agents</subject><subject>Biological and medical sciences</subject><subject>Conotoxin</subject><subject>Conotoxins - chemistry</subject><subject>Conotoxins - pharmacology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Molecular Conformation</subject><subject>Molecular Sequence Data</subject><subject>Neuropharmacology</subject><subject>Nicotinic acetylcholine receptor</subject><subject>Nicotinic Antagonists - chemistry</subject><subject>Nicotinic Antagonists - pharmacology</subject><subject>NMR solution structure</subject><subject>Parkinson Disease - physiopathology</subject><subject>Parkinson’s disease</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Binding</subject><subject>Protein Isoforms</subject><subject>Receptors, Nicotinic - chemistry</subject><subject>Receptors, Nicotinic - metabolism</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp9kM1OAyEYRYnR2PrzAG7MbFzOCAwzQExMTONf0sSFuibAgNK0QwO0sY_li_hM0rSpunHDF8K9hy8HgDMEKwRRezmp1ExXGEJeQVpB2OyBISItKeuao30whLxlJWS8HYCjGCcQQkw4OgQDxFvMas6HgD-nsNBpEeS0UDK6WFgfiq_PUvveJ__h-mLuk-n1qpB9V0QzNTq5pUurE3Bg5TSa0-08Bq93ty-jh3L8dP84uhmXmhCWSs0t7pRUnTYWGYggYTSfxrKGadkqrbFpOqTy1cg8JOGmodgqSpqadaY-Btcb7nyhZiZj-pSXFfPgZjKshJdO_H3p3bt480uBaUMobTIAbQA6-BiDsbsugmLtUUxE9ijWHgWkInvMnfPfn_40tuJy4GIbkFHLqQ2y1y7uchjlFOZr0NUmZ7KipTNBRO2yTtO5kE2Kzrt_1vgGBjOTog</recordid><startdate>20090815</startdate><enddate>20090815</enddate><creator>Turner, Matt</creator><creator>Eidemiller, Seth</creator><creator>Martin, Bryan</creator><creator>Narver, Andrew</creator><creator>Marshall, Joshua</creator><creator>Zemp, Logan</creator><creator>Cornell, Kenneth A.</creator><creator>McIntosh, J.M.</creator><creator>McDougal, Owen M.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20090815</creationdate><title>Structural basis for α-conotoxin potency and selectivity</title><author>Turner, Matt ; Eidemiller, Seth ; Martin, Bryan ; Narver, Andrew ; Marshall, Joshua ; Zemp, Logan ; Cornell, Kenneth A. ; McIntosh, J.M. ; McDougal, Owen M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-c9f2dbabdcef1e010487010ef858ca6bcc2e5d1b858ea1b8a49e572fb74538de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Amino Acid Sequence</topic><topic>Anticonvulsants. Antiepileptics. Antiparkinson agents</topic><topic>Biological and medical sciences</topic><topic>Conotoxin</topic><topic>Conotoxins - chemistry</topic><topic>Conotoxins - pharmacology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Molecular Conformation</topic><topic>Molecular Sequence Data</topic><topic>Neuropharmacology</topic><topic>Nicotinic acetylcholine receptor</topic><topic>Nicotinic Antagonists - chemistry</topic><topic>Nicotinic Antagonists - pharmacology</topic><topic>NMR solution structure</topic><topic>Parkinson Disease - physiopathology</topic><topic>Parkinson’s disease</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Binding</topic><topic>Protein Isoforms</topic><topic>Receptors, Nicotinic - chemistry</topic><topic>Receptors, Nicotinic - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Turner, Matt</creatorcontrib><creatorcontrib>Eidemiller, Seth</creatorcontrib><creatorcontrib>Martin, Bryan</creatorcontrib><creatorcontrib>Narver, Andrew</creatorcontrib><creatorcontrib>Marshall, Joshua</creatorcontrib><creatorcontrib>Zemp, Logan</creatorcontrib><creatorcontrib>Cornell, Kenneth A.</creatorcontrib><creatorcontrib>McIntosh, J.M.</creatorcontrib><creatorcontrib>McDougal, Owen M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Bioorganic & medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Turner, Matt</au><au>Eidemiller, Seth</au><au>Martin, Bryan</au><au>Narver, Andrew</au><au>Marshall, Joshua</au><au>Zemp, Logan</au><au>Cornell, Kenneth A.</au><au>McIntosh, J.M.</au><au>McDougal, Owen M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Structural basis for α-conotoxin potency and selectivity</atitle><jtitle>Bioorganic & medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2009-08-15</date><risdate>2009</risdate><volume>17</volume><issue>16</issue><spage>5894</spage><epage>5899</epage><pages>5894-5899</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>This manuscript provides the solution structure of α-conotoxin MII[E11A] and compares surface electrostatic maps for α-conotoxins that selectively inhibit α3β2 versus α6β2 nAChRs.
Parkinson’s disease is a debilitating movement disorder characterized by altered levels of α
6β
2∗ (∗ indicates the possible presence of additional subunits) nicotinic acetylcholine receptors (nAChRs) localized on presynaptic striatal catecholaminergic neurons. α-Conotoxin MII (α-CTx MII) is a highly useful ligand to probe α
6β
2 nAChRs structure and function, but it does not discriminate among closely related α
6∗ nAChR subtypes. Modification of the α-CTx MII primary sequence led to the identification of α-CTx MII[E11A], an analog with 500–5300-fold discrimination between α
6∗ subtypes found in both human and non-human primates. α-CTx MII[E11A] binds most strongly (femtomolar dissociation constant) to the high affinity α
6 nAChR, a subtype that is selectively lost in Parkinson’s disease. Here, we present the three-dimensional solution structure for α-CTx MII[E11A] as determined by two-dimensional
1H NMR spectroscopy to 0.13
±
0.09
Ǻ backbone and 0.45
±
0.08
Ǻ heavy atom root-mean-square deviation from mean structure. Structural comparisons suggest that the increased hydrophobic area of α-CTx MII[E11A] relative to other members of the α-CTx family may be responsible for its exceptionally high affinity for α6α4β2∗ nAChR as well as discrimination between α
6β
2 and α
3β
2 containing nAChRs. This finding may enable the rational design of novel peptide analogs that demonstrate enhanced specificity for α
6∗ nAChR subunit interfaces and provide a means to better understand nAChR structural determinants that modulate brain dopamine levels and the pathophysiology of Parkinson’s disease.</abstract><cop>Amsterdam</cop><pub>Elsevier Ltd</pub><pmid>19628399</pmid><doi>10.1016/j.bmc.2009.07.005</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0968-0896 |
ispartof | Bioorganic & medicinal chemistry, 2009-08, Vol.17 (16), p.5894-5899 |
issn | 0968-0896 1464-3391 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2754775 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Amino Acid Sequence Anticonvulsants. Antiepileptics. Antiparkinson agents Biological and medical sciences Conotoxin Conotoxins - chemistry Conotoxins - pharmacology Humans Medical sciences Molecular Conformation Molecular Sequence Data Neuropharmacology Nicotinic acetylcholine receptor Nicotinic Antagonists - chemistry Nicotinic Antagonists - pharmacology NMR solution structure Parkinson Disease - physiopathology Parkinson’s disease Pharmacology. Drug treatments Protein Binding Protein Isoforms Receptors, Nicotinic - chemistry Receptors, Nicotinic - metabolism |
title | Structural basis for α-conotoxin potency and selectivity |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A35%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Structural%20basis%20for%20%CE%B1-conotoxin%20potency%20and%20selectivity&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=Turner,%20Matt&rft.date=2009-08-15&rft.volume=17&rft.issue=16&rft.spage=5894&rft.epage=5899&rft.pages=5894-5899&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/j.bmc.2009.07.005&rft_dat=%3Cpubmed_cross%3E19628399%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c448t-c9f2dbabdcef1e010487010ef858ca6bcc2e5d1b858ea1b8a49e572fb74538de3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/19628399&rfr_iscdi=true |